We use cookies to ensure our website works properly and to personalise your experience. Cookies policy
Andhra University.
Porphyrias are rare inherited or acquired disorders of heme biosynthesis characterized by accumulation of porphyrins or their precursors and a heterogeneous spectrum of neurovisceral, cutaneous, hepatic, and systemic manifestations. Diagnostic delay remains an important clinical problem because symptoms may mimic common gastrointestinal, neurological, psychiatric, and dermatological disorders. Drug exposure is a particularly important modifiable factor in acute hepatic porphyrias, making drug–disease interactions and pharmacovigilance central to safe pharmacological care. This review integrates recent advances in biochemical and genetic diagnosis with practical considerations for medication safety, adverse drug reactions, hormonal triggers, pregnancy and lactation, and emerging targeted therapies. Particular attention is given to ALAS1-directed RNA interference with givosiran, biomarker development, and individualized risk assessment. Recent 2025–2026 clinical guidance and pharmacovigilance evidence are incorporated to distinguish established management from emerging strategies. The review emphasizes a pharmacist-oriented framework for prevention of drug-induced exacerbations, early recognition, appropriate laboratory confirmation, and personalized long-term monitoring
Porphyrias are orphan disease resulting from partial deficiencies of enzymes involved in heme synthesis, causing accumulation of porphyrins or their precursors¹. The disease spectrum is broad, and symptoms often mimic common neurological, gastrointestinal, or psychiatric conditions, leading to frequent misdiagnosis². Acute hepatic porphyrias are particularly dangerous due to life-threatening neurovisceral crises. Medications remain one of the most important modifiable triggers of disease exacerbation³. Understanding of drug safety and recent therapeutic innovations and emerged new therapies has shifted management toward prevention and disease modification.
Epidemiology of Porphyria
The prevalence of symptomatic acute porphyrias is estimated at 1–5 per 100,000 individuals globally¹⁵. Acute intermittent porphyria is the most common acute subtype, particularly in Northern Europe, while porphyria cutanea tarda is the most widespread worldwide⁵. Many individuals carry pathogenic mutations but remain asymptomatic, reflecting low disease penetrance⁶. In developing countries, underdiagnosis is common due to lack of awareness and limited laboratory facilities⁷.
Classification of Porphyria’s
Porphyrias are classified based on the primary site of porphyrin accumulation as hepatic or erythropoietic⁸. Hepatic porphyria’s include acute intermittent porphyria, variegate porphyria, hereditary coproporphyria, and porphyria cutanea tarda. Erythropoietic forms include erythropoietic protoporphyria and congenital erythropoietic porphyria⁹. Clinically, porphyrias are further divided into acute and cutaneous types, which aids diagnosis and management.
Causes of Porphyria
Porphyria is fundamentally caused by inherited defects in enzymes of the heme biosynthesis pathway¹⁰. However, genetic mutations alone are often insufficient to produce clinical disease. Environmental and acquired triggers such as porphyrinogenic drugs, alcohol, fasting, infections, smoking, and psychological stress play a crucial role¹¹. Porphyria cutanea tarda is strongly associated with liver disease, hepatitis C infection, iron overload, and estrogen exposure¹². These factors increase hepatic oxidative stress and disrupt heme metabolism.
Etiology of Porphyria
Defective enzyme activity results in accumulation of intermediates such as δ-aminolevulinic acid (ALA) and porphobilinogen (PBG), which are neurotoxic¹³. Reduced heme availability upregulates hepatic ALA synthase, further amplifying precursor production¹⁴. In acute porphyria’s, this leads to autonomic dysfunction, neuropathy, and psychiatric symptoms. In cutaneous porphyria’s, porphyrins absorb ultraviolet light, generating reactive oxygen species that damage skin tissues¹⁵.
Genetic Basis and Enzyme Defects
Most porphyrias are inherited in an autosomal dominant pattern with incomplete penetrance¹⁶. Mutations commonly involve genes encoding hydroxymethylbilane synthase, uroporphyrinogen decarboxylase, and protoporphyrinogen oxidase¹⁷. Genetic testing confirms diagnosis, allows family screening, and enables preventive counseling for asymptomatic carriers¹⁸.
Biomarkers in Porphyria
Biochemical biomarkers are essential for diagnosis and disease monitoring. Elevated urinary ALA and PBG during acute attacks are diagnostic hallmarks of acute hepatic porphyrias¹⁹. Plasma and fecal porphyria profiling helps differentiate subtypes²⁰. Plasma fluorescence emission scanning is useful in variegate porphyria²¹. Emerging biomarkers, including suppression of hepatic ALAS1 and homocysteine elevation during givosiran therapy, support personalized treatment strategies²².
Mechanisms of Drug-Induced Porphyria
Many drugs precipitate porphyria by inducing cytochrome P450 enzymes, increasing hepatic heme demand²³. This induction enhances ALA synthase activity and accumulation of toxic intermediates. Drugs affecting steroid metabolism or hepatic enzyme induction are particularly high risk²⁴. Understanding these mechanisms is essential for safe prescribing.
Adverse Drug Reactions in Porphyria
Drug-induced attacks often present with severe abdominal pain, vomiting, hypertension, neuropathy, and psychiatric disturbances²⁵. These reactions are frequently misinterpreted, leading to further exposure to unsafe medications²⁶. Early recognition and withdrawal of offending drugs are critical.
Usage of Safe and Unsafe Medications that affect porphyria
International porphyria drug databases classify medications based on porphyrinogenic risk²⁷. Opioid analgesics, beta-blockers, and penicillin antibiotics are generally safe. In contrast, barbiturates, carbamazepine, rifampicin, and certain antifungals are contraindicated²⁸.
Advances in Pharmacovigilance for detection of porphyria’s
Pharmacovigilance systems have improved detection of drug-related porphyria exacerbations²⁹. Analysis of adverse event databases has refined drug safety classifications and updated prescribing guidelines³⁰. Pharmacovigilance is especially important with newly approved therapies.
Common Drug Triggers
Frequently implicated drug classes include antiepileptics, hormonal contraceptives, antifungals, and some psychotropic agents³¹. Awareness of these triggers helps prevent avoidable attacks and improves patient counseling.
Pharmacogenomics and Personalized Medicine
Pharmacogenomic approaches explains disparity in drug response³². Genetic profiling may predict susceptibility to drug-induced porphyria and support individualized therapy³³.
Differential Diagnosis and Misdiagnosis of Porphyria
Diagnosis relies on clinical suspicion supported by biochemical testing. Measurement of urinary PBG during symptomatic periods is the most reliable initial investigation³⁴. Delayed diagnosis remains common and increases morbidity³⁵.
Biochemical diagnosis of acute porphyria is based on detecting significantly increased urinary porphobilinogen and δ-aminolevulinic acid, preferably measured during symptomatic episodes. Porphyrin profiling helps define the specific subtype, while genetic testing is used only to
Fig-1
Hormonal influence on porphyria disease
Hormonal fluctuations, particularly progesterone surges, can precipitate attacks in susceptible women⁴⁹. Individualized hormonal management is often necessary.
Pregnancy and Lactation considerations of porphyria
With appropriate monitoring and safe medication selection, pregnancy outcomes are generally favorable⁵⁰. However, drug safety remains a major concern.
Future Directions and Research Gaps
Future research should focus on long-term outcomes of RNA-based therapies, discovery of novel biomarkers, and improved access to diagnostics in resource-limited settings⁵¹.
CONCLUSION
Recent advances in biomarker research have significantly improved diagnostic precision, early detection, and longitudinal disease monitoring. The development of targeted and RNA-based therapies has shifted treatment strategies toward mechanism-driven and disease-modifying approaches. Careful drug selection, pharmacovigilance and patient education gives optimal outcomes. Enhanced understanding of drug–disease interactions has strengthened porphyria preventive care and reduced acute exacerbations. Collectively, these innovations support a more personalized outcomes.
Novelty and Clinical Relevance
The distinguishing focus of this review is the integration of diagnostic advances with medication safety and pharmacovigilance. Rather than presenting emerging therapies alone, the review links porphyrinogenic drug exposure, adverse drug reactions, biochemical confirmation, genetic clarification, and targeted treatment within a pharmacist-oriented framework. This approach is intended to support practical prevention of avoidable exacerbations while highlighting areas where evidence remains limited.
|
Clinical domain |
Key assessment |
Pharmacological relevance |
Practical implication |
|
Acute hepatic porphyria |
Urinary ALA/PBG during suspected attacks |
Avoid porphyrinogenic triggers |
Early testing and medication review |
|
Drug safety |
Check drug-specific porphyrogenicity |
Prevent drug-induced attacks |
Use validated specialist drug-safety resources |
|
Recurrent attacks |
Attack frequency and biochemical activity |
Hemin or givosiran may be considered |
Long-term monitoring is required |
|
Erythropoietic/cutaneous forms |
Porphyrin pattern and clinical phenotype |
Treatment differs by subtype |
Avoid applying AHP drug rules indiscriminately |
|
Pharmacovigilance |
Adverse-event and post-marketing signals |
Refines safety knowledge for newer therapies |
Report and monitor suspected adverse events |
REFERENCES
Puy H, Gouya L, Deybach JC. Porphyrias. Lancet. 2010; 375(9718):924–37.
Puy H, Gouya L, Deybach JC. Porphyrias. Lancet. 2010; 375(9718):924–37.
Reem Muayad Ahmed, Ali Abdullah Ahmed AL-Salami, Porphyria’s Molecular Pathogenesis, Diagnostic Advances, and Emerging Therapeutic Strategies, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 10, 281-287, https://doi.org/10.5281/zenodo.23120087
10.5281/zenodo.23120087